4.6 Article

Cardiac inflammation and diastolic dysfunction in hypercholesterolemic rabbits

Journal

PLOS ONE
Volume 14, Issue 8, Pages -

Publisher

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0220707

Keywords

-

Ask authors/readers for more resources

Background Left ventricular diastolic dysfunction (LVDD) is present in more than 50% of patients suffering from heart failure. LVDD animal models are limited and its underlying mechanisms remain largely unknown. Aortic valve stenosis (AVS) may cause LVDD, and we recently reported LVDD in an AVS rabbit model. Here we aimed to develop a rabbit model of LVDD without AVS. Methods Rabbits were fed with a 0.5% cholesterol-enriched diet (n = 9) or normal diet (n = 8) until they developed LVDD defined by a value of the echocardiographic parameter E/Em ratio higher than the mean at baseline +2SD. Rabbits were then fed a 0.2% cholesterol-enriched diet for 4 weeks (average total diet duration: 20 weeks). Detailed cardiac structure and function measurements were assessed by echocardiography at baseline, weeks 8, 12 and 14 to 20, when applicable. Histological analyses and RT-qPCR were performed on LV samples. Results The hypercholesterolemic diet induced LVDD without systolic dysfunction or AVS, as shown by multiple echocardiographic parameters, including early filling mitral peak velocity and deceleration rate, Em/Am ratio and E/Em ratio (all p<0.05), and by increased cardiac mRNA expression of brain natriuretic peptide (Bnp). Cardiac expression of mRNA for Nox2, Vcam1, Mmp12, Mmp12/Timp1, Il1b and Col1/Col3 ratios was also higher in these rabbits (p<0.05). In contrast, cardiac Sod2 mRNA expression was reduced in hypercholesterolemic rabbits compared to controls. Conclusion Rabbits fed with a cholesterol-enriched diet develop LVDD with preserved systolic function and evidence of cardiac inflammation and oxidative stress. This rabbit model may be used in future studies to test treatment strategies against LVDD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Letter Cardiac & Cardiovascular Systems

Cardiovascular risk of chronic coronary syndrome patients according to vascular phenotype, diabetes, and smoking

Alexandre Gautier, Gregory Ducrocq, Yedid Elbez, Kim M. Fox, Roberto Ferrari, Ian Ford, Jean-Claude Tardif, Michal Tendera, Laurent J. Feldman, Philippe Gabriel Steg

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2022)

Letter Cardiac & Cardiovascular Systems

Pattern of Atrial Fibrillation and Cognitive Function in Young Patients With Atrial Fibrillation and Low CHADS2 Score: Insights From the BRAIN-AF Trial

Amanda K. Morrow, T. Andrew Zabel, Jennifer Dodson, Sarah A. Korth

CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY (2022)

Article Cardiac & Cardiovascular Systems

Adenylate cyclase type 9 antagonizes cAMP accumulation and regulates endothelial signalling involved in atheroprotection

Yohann Rautureau, Marianne Berlatie, Daniel Rivas, Kurunradeth Uy, Alexandre Blanchette, Geraldine Miquel, Marie-Eve Higgins, Melanie Mecteau, Audrey Nault, Louis Villeneuve, Veronique Lavoie, Gabriel Theberge-Julien, Genevieve Brand, Line Lapointe, Maxime Denis, Camille Rosa, Annik Fortier, Lucie Blondeau, Marie-Claude Guertin, Marie-Pierre Dube, Eric Thorin, Jonathan Ledoux, David Rhainds, Eric Rheaume, Jean-Claude Tardif

Summary: ADCY9 gene plays a role in determining atherosclerotic outcomes in patients and in mice it has been shown to potentiate endothelial function and inhibit atherogenesis. The inactivation of Adcy9 leads to increased cAMP accumulation in response to certain activators and enhances endothelial-dependent vasodilation. Additionally, ADCY9 can regulate endothelial permeability and actin cytoskeleton in response to thrombin, affecting the development of atherosclerosis.

CARDIOVASCULAR RESEARCH (2023)

Article Biochemistry & Molecular Biology

ExPheWas: a platform for cis-Mendelian randomization and gene-based association scans

Marc-Andre Legault, Louis-Philippe Lemieux Perreault, Jean-Claude Tardif, Marie-Pierre Dube

Summary: ExPheWas is a gene-based phenome-wide association study browser and platform, providing interactive visualizations and data tools for conducting gene-based Mendelian randomization studies to understand the relationship between genes and phenotypes.

NUCLEIC ACIDS RESEARCH (2022)

Article Cardiac & Cardiovascular Systems

Impact of Icosapent Ethyl on Cardiovascular Risk Recuction in Patients With Heart Failure in REDUCE-IT

Senthil Selvaraj, Deepak L. Bhatt, Ph Gabriel Steg, Michael Miller, Eliot A. Brinton, Terry A. Jacobson, Rebecca A. Juliano, Lixia Jiao, Jean-Claude Tardif, Christie M. Ballantyne

Summary: This study aimed to investigate the treatment effects of icosapent ethyl in patients with heart failure (HF). The results showed that icosapent ethyl reduced triglyceride and hs-CRP levels in patients with HF, and had similar cardiovascular risk reduction effects.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2022)

Article Cardiac & Cardiovascular Systems

Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial

Jean Claude Tardif, Marc A. Pfeffer, Simon Kouz, Wolfgang Koenig, Aldo P. Maggioni, John J. McMurray, Vincent Mooser, David D. Waters, Jean C. Gregoire, Philippe L. L'Allier, J. Wouter Jukema, Harvey D. White, Therese Heinonen, Donald M. Black, Fouzia Laghrissi-Thode, Sylvie Levesque, Marie Claude Guertin, Marie Pierre Dube, Dal-GenE Investigators

Summary: The dal-GenE study aimed to test the pharmacogenetic hypothesis that the effect of dalcetrapib on cardiovascular events is influenced by an ADCY9 gene polymorphism. However, the study found that dalcetrapib did not significantly reduce the risk of occurrence of ischemic cardiovascular events. Further trials are needed to investigate the effect of dalcetrapib on patients with the AA genotype.

EUROPEAN HEART JOURNAL (2022)

Article Cardiac & Cardiovascular Systems

Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking

Michael Miller, Deepak L. Bhatt, Ph Gabriel Steg, Eliot A. Brinton, Terry A. Jacobson, Lixia Jiao, Jean-Claude Tardif, Christie M. Ballantyne, Matthew Budoff, R. Preston Mason

Summary: The study found that the use of IPE can reduce the risk of cardiovascular disease in smokers to the level observed in non-smokers.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2023)

Article Biochemistry & Molecular Biology

Dalcetrapib and anacetrapib increase apolipoprotein E-containing HDL in rabbits and humans

Mathieu R. Brodeur, David Rhainds, Daniel Charpentier, Marie Boule, Teodora Mihalache-Avram, Melanie Mecteau, Genevieve Brand, Valerie Pedneault-Gagnon, Annik Fortier, Eric J. Niesor, Eric Rheaume, Cyrille Maugeais, Jean-Claude Tardif

Summary: The effects of CETP inhibitors on HDL particle composition were studied in rabbits and humans. The study found that these inhibitors increased the concentration of large apo E-containing HDL particles, which can interact with hepatic LDL receptors.

JOURNAL OF LIPID RESEARCH (2023)

Article Biochemistry & Molecular Biology

High-density lipoprotein cholesterol efflux capacity in patients with obstructive sleep apnea and its relation with disease severity

Reza Fadaei, Samaneh Mohassel Azadi, Eric Rheaume, Habibolah Khazaie

Summary: Obstructive sleep apnea (OSA) is associated with an increased risk of cardiovascular disease (CVD), and HDL cholesterol efflux capacity (CEC) may be impaired in OSA patients, potentially contributing to the risk of CVD.

LIPIDS IN HEALTH AND DISEASE (2022)

Article Cardiac & Cardiovascular Systems

Optimal or standard control of systolic and diastolic blood pressure across risk factor categories in patients with chronic coronary syndromes

Emmanuelle Vidal-Petiot, Yedid Elbez, Jules Mesnier, Gregory Ducrocq, Ian Ford, Michal Tendera, Roberto Ferrari, Jean-Claude Tardif, Kim M. Fox, Philippe Gabriel Steg

Summary: This study compared the benefits of strict vs. standard control of blood pressure with the potential benefits of controlling other modifiable risk factors in patients with chronic coronary syndromes. The results showed that the benefit associated with strict blood pressure control was marginal and driven only by the diastolic component, while uncontrolled other risk factors were associated with a gradually increasing risk. Therefore, optimizing other risk factors should be prioritized over further reduction of systolic blood pressure. The optimal blood pressure target in chronic coronary syndromes may be <=139/79 mmHg.

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2023)

Article Oncology

Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors

Maxine Sun, Marie-Christyne Cyr, Johanna Sandoval, Louis-Philippe Lemieux Perreault, Lambert Busque, Jean-Claude Tardif, Marie-Pierre Dube

Summary: This study analyzed a cohort of 48,919 cancer patients from the UK Biobank and found that individuals with mosaic chromosomal alterations (mCA) are at an increased risk of death from cardiovascular disease (CVD), particularly in patients with kidney cancer and breast cancer.

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2023)

Article Cardiac & Cardiovascular Systems

Association between coffee or tea consumption and cardiovascular outcomes in patients with stable coronary artery disease: Analysis from the CLARIFY registry

Jeremie Abtan, Gregory Ducrocq, Yedid Elbez, Roberto Ferrari, Ian Ford, Kim M. Fox, Jean-Claude Tardif, Michal Tendera, Nicolas Danchin, Alexander Parkhomenko, Christopher M. Reid, Gabriel Steg

Summary: There is no association between consumption of coffee or tea and ischemic outcomes or all-cause mortality in outpatients with stable coronary artery disease.

ARCHIVES OF CARDIOVASCULAR DISEASES (2023)

Article Cardiac & Cardiovascular Systems

Autoimmune Atrial Fibrillation

Ange Maguy, Yuvaraj Mahendran, Jean-Claude Tardif, David Busseuil, Jin Li

Summary: This study explores the association between autoantibodies targeting cardiac ion channels and unexplained AF. They found a common autoantibody response against K(ir)3.4 protein in patients with AF, even before the development of clinically apparent AF. Functional studies and a mouse model of K(ir)3.4 autoimmunity support the causal relationship between K(ir)3.4 autoantibodies and AF.

CIRCULATION (2023)

Article Cardiac & Cardiovascular Systems

New-onset atrial fibrillation and chronic coronary syndrome in the CLARIFY registry

Alexandre Gautier, Fabien Picard, Gregory Ducrocq, Yedid Elbez, Kim M. Fox, Roberto Ferrari, Ian Ford, Jean-Claude Tardif, Michal Tendera, Philippe Gabriel Steg

Summary: This study found that new-onset atrial fibrillation (NOAF) is common among patients with chronic coronary syndromes (CCS) and is associated with increased risk of cardiovascular adverse events. Age, body mass index, glomerular filtration rate, ethnicity, alcohol intake, and left ventricular ejection fraction were identified as predictors of NOAF. The study suggests that more intensive preventive measures and systematic screening for atrial fibrillation should be considered in this patient population.

EUROPEAN HEART JOURNAL (2023)

Article Health Care Sciences & Services

CathAI: fully automated coronary angiography interpretation and stenosis estimation

Robert Avram, Jeffrey E. Olgin, Zeeshan Ahmed, Louis Verreault-Julien, Alvin Wan, Joshua Barrios, Sean Abreau, Derek Wan, Joseph E. Gonzalez, Jean-Claude Tardif, Derek Y. So, Krishan Soni, Geoffrey H. Tison

Summary: This study presents a fully automated approach to interpret angiographic coronary artery stenosis using neural networks. The algorithms were trained on a large dataset and validated on real-world angiograms from multiple institutions. The results demonstrate the potential of neural networks in automated analysis of coronary artery stenosis.

NPJ DIGITAL MEDICINE (2023)

No Data Available